# Newleos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newleos-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: https://newleos.com/
- Total disclosed funding: $109M
- Latest round: Grant (Nov 3, 2026)
- Investors on record: 6

## About

Based in Massachusetts, US, Newleos Therapeutics, Inc. operates as a neuroscience company which specializes in developing drugs in neuropsychiatry. The company was founded by Longwood, Christoph Westphal, Miguel Sobral and Rob Hadfield. In February 2025, Newleos Therapeutics raised USD 93.5 million in series A funding led by investor Goldman Sachs Asset Management, with participation from other investors Novo Holdings, Longwood Fund, Data Collective and Arkin Bio Capital.

Newleos’ lead product, NTX-1955, is a first-in-class GABAA-?1 selective positive allosteric modulator (PAM) designed to treat anxiety disorders with fewer side effects compared to current therapies. Other clinical-stage assets in the pipeline include NTX-1472 for social anxiety, NTX-2001 for substance use disorders, and NTX-1511 for cognitive impairment. These therapies target novel mechanisms in the brain, such as the GABAA, V1a, and TAAR1 receptors, addressing major unmet needs in neuropsychiatry. The company plans to utilize the February 2025 funding to develop four cast-off drugs from Roche’s neuropsychiatric division.

The company plans to utilize the February 2025 funding to develop four cast-off drugs from Roche’s neuropsychiatric division.

## Funding rounds

- Grant, Nov 3, 2026, $16M — National Institute on Drug Abuse (NIDA)
- Series A, Feb 10, 2025, $93M — Novo Holdings, Goldman Sachs Asset Management, Longwood Fund, DCVC, Arkin Capital

## Investors

- Novo Holdings — Series A
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series A
- National Institute on Drug Abuse (NIDA) — Grant